Cargando…

Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation

BACKGROUND: There are no proven effective treatments that can reduce the mortality in heart failure with preserved ejection fraction (HFpEF), probably due to its heterogeneous nature which will weaken the effect of therapy in clinical studies. We evaluated the effect of beta-blocker treatment in HFp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yanhua, Guo, Suxia, Huang, Ziyao, Deng, Chunhua, Chen, Lihua, Zhou, Guoxiang, Jian, Zhengwei, He, Ruping, Huang, Zhichao, Yao, Yongzhao, Lu, Jiongbin, Hua, Zhiwen, Huang, Yuli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243006/ https://www.ncbi.nlm.nih.gov/pubmed/32454997 http://dx.doi.org/10.1155/2020/3059864

Ejemplares similares

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

Aldosterone Antagonism in Atrial Fibrillation: Implications for AF‐Predominant HFpEF
por: Ho, Jennifer E.
Publicado: (2020)

The “Obesity Paradox” in Patients With HFpEF With or Without Comorbid Atrial Fibrillation
por: Guo, Linjuan, et al.
Publicado: (2022)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
por: Borlaug, Barry A., et al.
Publicado: (2023)

Left-Side Pressure Index for All-Cause Mortality in Older Adults with HFpEF: Diagnostic Potential for HFpEF and Possible View for HFrEF
por: Hoshida, Shiro
Publicado: (2023)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial
por: Backhaus, Sören J., et al.
Publicado: (2022)

Case of Ischemic Hepatitis in the Setting of HFpEF Exacerbated by Persistent Atrial Fibrillation
por: McClairen, Christian, et al.
Publicado: (2022)

Prognostic Impact of Echocardiographic Congestion Grade in HFpEF With and Without Atrial Fibrillation
por: Abe, Haruhiko, et al.
Publicado: (2022)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)

Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants
por: Hiebert, John B., et al.
Publicado: (2016)

Diet-Induced Obesity HFpEF Murine Models
por: Carbone, Salvatore, et al.
Publicado: (2018)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019)

Decoding the Pathophysiology of HFpEF With High-Resolution Phenotyping
por: Houstis, Nicholas E.
Publicado: (2020)

Understanding HFpEF With Obesity: Will Pigs Come to the Rescue?
por: Kass, David A.
Publicado: (2021)

Turning Pressure Into Success: Preload Restriction in HFpEF?
por: Atkins, Jessica, et al.
Publicado: (2021)

Renin Feedback Is an Independent Predictor of Outcome in HFpEF
por: Binder, Christina, et al.
Publicado: (2021)

Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
por: Bonanni, Alice, et al.
Publicado: (2023)

The role of imaging in the selection of patients for HFpEF therapy
por: Baron, Tomasz, et al.
Publicado: (2023)

HFpEF and Atrial Fibrillation: The Enigmatic Interplay of Dysmetabolism, Biomarkers, and Vascular Endothelial Dysfunction
por: Bosanac, Jure, et al.
Publicado: (2022)

Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation
por: Guo, Linjuan, et al.
Publicado: (2023)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Reply: Diet-Induced Obesity HFpEF Murine Models
por: Valero-Muñoz, Maria, et al.
Publicado: (2018)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities
por: Cuijpers, Ilona, et al.
Publicado: (2020)

Cat-apulting Toward a Molecular Understanding of HFpEF
por: Robinson, Emma L., et al.
Publicado: (2021)

Hemodynamic force analysis is not ready for clinical trials on HFpEF
por: Arvidsson, Per M., et al.
Publicado: (2022)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
por: Zhu, Zhaowei, et al.
Publicado: (2021)

Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?
por: Justo da Silva, Gustavo Jose, et al.
Publicado: (2021)

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
por: Barilli, Maria, et al.
Publicado: (2022)

New antidiabetic therapy and HFpEF: light at the end of tunnel?
por: Tadic, Marijana, et al.
Publicado: (2021)

Electrophysiological findings in HFpEF patients presenting for AF ablation
por: Lee, J, et al.
Publicado: (2023)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

OR19-2 Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) with Low and High Dose of Triiodothyronine: an Animal Model of Metabolic Syndrome with HFpEF
por: Almeida-Coelho, João, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5cvb6rqjp77lpi394298e826kc